Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 25

Sort by

Sort Order Select

Journal Articles

PYGO2-MDR1 Axis in Multiple Myeloma Patients with 1q21 Amplification As Promising Target to Overcome Carfilzomib Resistance

Nicolas Thomas Iannozzi, Jessica Burroughs Garcia, Valentina Marchica, Valentina Franceschi, Denise Toscani, Rosanna Vescovini, Vincenzo Raimondi, Oxana Lungu, Giannalisa Todaro, Gabriella Sammarelli, Matteo Scita, Federica Librale, Anna Benedetta Dalla Palma, Gaetano Donofrio, Paola Storti, Luca Agnelli, Giancarlo Pruneri, Nicola Giuliani

Blood (2023) 142 (Supplement 1): 6575.

https://doi.org/10.1182/blood-2023-181685

Published: 2023

Journal Articles

Identification of Clinical-Biological Features of Newly Diagnosed Early Relapse Multiple Myeloma Patients Eligible for Autologous Stem Cell Transplantation

Lorenzo Cillo, Anna Benedetta Dalla Palma, Matteo Scita, Federica Librale, Matia Bernardi, Stefania Ricci, Gabriella Sammarelli, Giannalisa Todaro, Mario Pedrazzoni, Nicola Giuliani

Blood (2023) 142 (Supplement 1): 6637.

https://doi.org/10.1182/blood-2023-182835

Published: 2023

Journal Articles

Dedalo: Phase II Study of Daratumumab Plus Pomalidomide and Dexamethasone (DPd) in Patients with Relapsed/Refractory Multiple Myeloma and 17p Deletion

Vittorio Montefusco, Anna Maria Cafro, Gloria Margiotta Casaluci, Francesca Patriarca, Roberto Mina, Mattia D'Agostino, Andrea Capra, Claudia Priola, Anna Benedetta Dalla Palma, Rita Rizzi, Angelo Genua, Maria Teresa Petrucci, Laura Paris, Angelo Belotti, Michele Cavo, Concetta Conticello, Carmelo Carlo-Stella, Mario Boccadoro

Blood (2022) 140 (Supplement 1): 10193–10195.

https://doi.org/10.1182/blood-2022-156691

Published: 2022

Journal Articles

Glutamate Metabolism Shapes Osteoclast Differentiation: New Potential Therapeutic Target to Block Osteoclastic Bone Resorption in Multiple Myeloma Patients

Denise Toscani, Oxana Lungu, Vincenzo Raimondi, Martina Chiu, Nicolas Thomas Iannozzi, Jessica Burroughs Garcia, Anna Benedetta Dalla Palma, Matteo Scita, Matia Bernardi, Valentina Marchica, Paola Storti, Ovidio Bussolati, Nicola Giuliani

Blood (2022) 140 (Supplement 1): 4217–4218.

https://doi.org/10.1182/blood-2022-166654

Published: 2022

Journal Articles

Identification of the Proteasome Subunits PSMB4 and PSMD4 As Novel Targets in Multiple Myeloma Patients Carrying 1q21 Amplification

Jessica Burroughs Garcia, Paola Storti, Nicolas Thomas Iannozzi, Laura Notarfranchi, Denise Toscani, Valentina Marchica, Vincenzo Raimondi, Luca Agnelli, Valentina Franceschi, Giannalisa Todaro, Oxana Lungu, Matia Bernardi, Matteo Scita, Gabriella Sammarelli, Gaetano Donofrio, Anna Benedetta Dalla Palma, Nicola Giuliani

Blood (2022) 140 (Supplement 1): 6750–6751.

https://doi.org/10.1182/blood-2022-165974

Published: 2022

Journal Articles

PSMB4 and PSMD4 Are Correlated with 1q21 Amplification in CD138 + Plasma Cells: New Potential Druggable Targets in Myeloma Patients

Jessica Burroughs-Garcia, Paola Storti, Luca Agnelli, Denise Toscani, Valentina Marchica, Gabriella Sammarelli, Giannalisa Todaro, Vincenzo Raimondi, Valentina Franceschi, Naomi Soressi, Anna Benedetta Dalla Palma, Laura Notarfranchi, Gaetano Donofrio, Nicola Giuliani

Blood (2021) 138 (Supplement 1): 2657.

https://doi.org/10.1182/blood-2021-150198

Published: 2021

Journal Articles

PD-L1/PD-1 Pattern of Distribution within Bone Marrow Microenvironment Cells in Patients with Smoldering Myeloma and Active Multiple Myeloma

Federica Costa, Rosanna Vescovini, PhD, Laura Notarfranchi, Paola Storti, PhD, Valentina Marchica, MS, Anna Benedetta Dalla Palma, MD, Cristina Manferdini, BS, Denise Toscani, PhD, Rosalba Eufemiese, MS, Jessica Burroughs, PhD, Gina Lisignoli, PhD, Nicola Giuliani

Blood (2020) 136 (Supplement 1): 49–50.

https://doi.org/10.1182/blood-2020-139275

Published: 2020

Journal Articles

Short-Term Risk for Progression in Patients with Smoldering Multiple Myeloma: The Impact of CD56 Expression

Laura Notarfranchi, Rosanna Vescovini, PhD, Roberta Segreto, MS, Sabrina Bonomini, MS, Paola Storti, PhD, Valentina Marchica, MS, Federica Costa, Gabriella Sammarelli, PhD, Giannalisa Todaro, PhD, Maria Teresa Catarozzo, MS, Dario De Giovanni, MD, Vincenza Fabiano, MD, Anna Benedetta Dalla Palma, MD, Nicola Giuliani

Blood (2020) 136 (Supplement 1): 11.

https://doi.org/10.1182/blood-2020-139214

Published: 2020

Journal Articles

Short-Term Risk of Progression of Patients with Asymptomatic Monoclonal Gammopathies to Active Multiple Myeloma: The Critical Impact of the Tumoral Mass

Anna Benedetta Dalla Palma, MD, Laura Notarfranchi, MD, Jessica Crosara, MD, Mario Pedrazzoni, MD, Fabrizio Accardi, MD, Valentina Marchica, MS, Denise Toscani, PhD, Emanuela Vicario, PhD, Paola Storti, PhD, Nicola Giuliani

Blood (2019) 134 (Supplement_1): 1795.

https://doi.org/10.1182/blood-2019-128252

Published: 2019

Journal Articles

Myeloma-Induced Alterations of Glutamine Metabolism Impair Bone Microenvironment Niche in Multiple Myeloma Patients

Denise Toscani, PhD, Martina Chiu, PhD, Giuseppe Taurino, MS, Emanuela Vicario, MS, Valentina Marchica, MS, Fabrizio Accardi, MD, Anna Benedetta Dalla Palma, MD, Paola Storti, PhD, Gaetano Donofrio, PhD, Franco Aversa, MD, Ovidio Bussolati, MD PhD, Nicola Giuliani, MD PhD

Blood (2018) 132 (Supplement 1): 4481.

https://doi.org/10.1182/blood-2018-99-111337

Published: 2018

Journal Articles

CD14 + CD16 + Monocyte Binding to Myeloma Cells Is Required for Daratumumab Dependent Killing in Multiple Myeloma Patients

Paola Storti, PhD, Rosanna Vescovini, PhD, Valentina Marchica, MS, Marina Bolzoni, PhD, Federica Costa, MS, Emanuela Vicario, MS, Denise Toscani, PhD, Anna Benedetta Dalla Palma, MD, Fabrizio Accardi, MD, Fabio Malavasi, MD, Franco Aversa, MD, Nicola Giuliani, MD PhD

Blood (2018) 132 (Supplement 1): 3200.

https://doi.org/10.1182/blood-2018-99-112873

Published: 2018

Journal Articles

Relationship between Bone Marrow PD-1 and PD-L1 Expression and the Presence of Osteolytic Bone Disease in Multiple Myeloma Patients

Federica Costa, MS, Marina Bolzoni, PhD, Rosanna Vescovini, PhD, Fabrizio Accardi, MD, Anna Benedetta Dalla Palma, MD, Federica De Luca, PhD, Valentina Marchica, MS, Denise Toscani, PhD, Emanuela Vicario, MS, Paola Storti, PhD, Franco Aversa, MD, Nicola Giuliani, MD PhD

Blood (2018) 132 (Supplement 1): 3183.

https://doi.org/10.1182/blood-2018-99-118200

Published: 2018

Journal Articles

Bone Marrow DKK-1 Levels in Smoldering Multiple Myeloma Patients: A New Independent Risk Factor for Progression

Benedetta Dalla Palma, MD, Valentina Marchica, Fabrizio Accardi, MD, Daniela Guasco, Laura Notarfranchi, MD, Federica Costa, Martina Caviola, Federica De Luca, Luisa Craviotto, MD, Mario Pedrazzoni, MD PhD, Franco Aversa, MD, Nicola Giuliani, MD PhD

Blood (2016) 128 (22): 4452.

https://doi.org/10.1182/blood.V128.22.4452.4452

Published: 2016

Journal Articles

Lenalidomide Increases Human Dendritic Cell Maturation in Multiple Myeloma Modulating Both Monocyte Differentiation and Mesenchymal Stromal Cell Inhibitory Properties through Ikaros and Casein Kinase 1 Degradation, Respectively

Federica Costa, Marina Bolzoni, PhD, Rosanna Vescovini, PhD, Valentina Marchica, Fabrizio Accardi, MD, Laura Notarfranchi, MD, Benedetta Dalla Palma, MD, Cristina Manferdini, Gina Lisignoli, Sabrina Manni, PhD, Francesco Piazza, MD, Franco Aversa, MD, Nicola Giuliani, MD PhD

Blood (2016) 128 (22): 4464.

https://doi.org/10.1182/blood.V128.22.4464.4464

Published: 2016

Journal Articles

Addition of Bortezomib to High Dose Melphalan As Conditioning Regimen for Autologous Stem Cell Transplantation Improves the Response Rate in Newly Diagnosed Multiple Myeloma Patients

Benedetta Dalla Palma, MD, Lucia Prezioso, MD PhD, Fabrizio Accardi, MD, Stefano Bisbano, Federica De Luca, Franco Aversa, MD, Nicola Giuliani, MD PhD

Blood (2016) 128 (22): 4647.

https://doi.org/10.1182/blood.V128.22.4647.4647

Published: 2016

Journal Articles

Expression Profile of CD38 and Related Ectoenzymes in Myeloma Bone Niche: A Rational Basis for the Use of Daratumumab to Inhibit Osteoclast Formation and Activity

Denise Toscani, PhD, Marina Bolzoni, PhD, Federica Costa, Valeria Quarona, Valentina Marchica, Cristina Mancini, MD, Eugenia Martella, MD, Sabrina Bonomini, Paola Storti, PhD, Antonella Chillemi, PhD, Fabrizio Accardi, MD, Benedetta Dalla Palma, MD, Luisa Craviotto, MD, Fabio Malavasi, MD, Franco Aversa, MD, Nicola Giuliani, MD PhD

Blood (2015) 126 (23): 2959.

https://doi.org/10.1182/blood.V126.23.2959.2959

Published: 2015

Journal Articles

The Myeloma Cells Escape from Bone Marrow to Skin Extramedullary Localization upon Bortezomib Resistance: Role of CXCR4

Valentina Marchica, Fabrizio Accardi, MD, Paola Storti, PhD, Cristina Mancini, MD, Eugenia Martella, MD, Marina Bolzoni, PhD, Katia Todoerti, Chiara Schifano, Sabrina Bonomini, Benedetta Dalla Palma, MD, Magda Marcatti, MD, Maurilio Ponzoni, MD, Antonino Neri, MD, Franco Aversa, MD, Nicola Giuliani, MD PhD

Blood (2015) 126 (23): 5315.

https://doi.org/10.1182/blood.V126.23.5315.5315

Published: 2015

Journal Articles

Overexpression of Pro-Osteoclastogenic Cytokine Receptors and Chemokines By Bone Marrow CD14 + Monocytes of Multiple Myeloma (MM) Patients As Compared to Smoldering MM (SMM) and Monoclonal Gammopathy of Uncertain Significance (MGUS): Role of Interleukin(IL)-21 Receptor/IL-21 Axis in MM-Induced Osteoclastogenesis

Marina Bolzoni, Domenica Ronchetti, Paola Storti, PhD, Daniela Guasco, Valentina Marchica, Luca Agnelli, PhD, Benedetta Dalla Palma, MD, Fabrizio Accardi, MD, Federica Costa, Denise Toscani, Sabrina Bonomini, Benjamin Thomas, PhD, Antonino Neri, Franco Aversa, MD, Nicola Giuliani, MD PhD

Blood (2014) 124 (21): 28.

https://doi.org/10.1182/blood.V124.21.28.28

Published: 2014

Journal Articles

Relationship Between Presence Of Osteolytic Lesions, Cytogenetic Features and Bone Marrow Levels Of Cytokines and Chemokines In Multiple Myeloma Patients: Role Of Chemokine (C-C motif) Ligand 20

Nicola Giuliani, MD, PhD, Benedetta Dalla Palma, MD, Daniela Guasco, Mario Pedrazzoni, MD, PhD, Marina Bolzoni, Gabriella Sammarelli, PhD, Paola Storti, PhD, Angelica Spolzino, MD, Luisa Craviotto, MD, Massimo De Filippo, MD, Livia Ruffini, MD, Franco Aversa, MD

Blood (2013) 122 (21): 3110.

https://doi.org/10.1182/blood.V122.21.3110.3110

Published: 2013

Journal Articles

Myeloma-Induced Osteocyte Death Was Blunted By Proteasome Inhibitors Through The Modulation Of Autophagy

Denise Toscani, Carla Palumbo, MD, Benedetta Dalla Palma, MD, Marina Bolzoni, Marzia Ferretti, Paola Sena, Daniela Guasco, Eugenia Martella, MD, Franco Aversa, MD, Nicola Giuliani, MD, PhD

Blood (2013) 122 (21): 3096.

https://doi.org/10.1182/blood.V122.21.3096.3096

Published: 2013

NARROW

PYGO2-MDR1 Axis in Multiple Myeloma Patients with 1q21 Amplification As Promising Target to Overcome Carfilzomib Resistance

Identification of Clinical-Biological Features of Newly Diagnosed Early Relapse Multiple Myeloma Patients Eligible for Autologous Stem Cell Transplantation

Dedalo: Phase II Study of Daratumumab Plus Pomalidomide and Dexamethasone (DPd) in Patients with Relapsed/Refractory Multiple Myeloma and 17p Deletion

Glutamate Metabolism Shapes Osteoclast Differentiation: New Potential Therapeutic Target to Block Osteoclastic Bone Resorption in Multiple Myeloma Patients

Identification of the Proteasome Subunits PSMB4 and PSMD4 As Novel Targets in Multiple Myeloma Patients Carrying 1q21 Amplification

PSMB4 and PSMD4 Are Correlated with 1q21 Amplification in CD138 + Plasma Cells: New Potential Druggable Targets in Myeloma Patients

PD-L1/PD-1 Pattern of Distribution within Bone Marrow Microenvironment Cells in Patients with Smoldering Myeloma and Active Multiple Myeloma

Short-Term Risk for Progression in Patients with Smoldering Multiple Myeloma: The Impact of CD56 Expression

Short-Term Risk of Progression of Patients with Asymptomatic Monoclonal Gammopathies to Active Multiple Myeloma: The Critical Impact of the Tumoral Mass

Myeloma-Induced Alterations of Glutamine Metabolism Impair Bone Microenvironment Niche in Multiple Myeloma Patients

CD14 + CD16 + Monocyte Binding to Myeloma Cells Is Required for Daratumumab Dependent Killing in Multiple Myeloma Patients

Relationship between Bone Marrow PD-1 and PD-L1 Expression and the Presence of Osteolytic Bone Disease in Multiple Myeloma Patients

Bone Marrow DKK-1 Levels in Smoldering Multiple Myeloma Patients: A New Independent Risk Factor for Progression

Lenalidomide Increases Human Dendritic Cell Maturation in Multiple Myeloma Modulating Both Monocyte Differentiation and Mesenchymal Stromal Cell Inhibitory Properties through Ikaros and Casein Kinase 1 Degradation, Respectively

Addition of Bortezomib to High Dose Melphalan As Conditioning Regimen for Autologous Stem Cell Transplantation Improves the Response Rate in Newly Diagnosed Multiple Myeloma Patients

Expression Profile of CD38 and Related Ectoenzymes in Myeloma Bone Niche: A Rational Basis for the Use of Daratumumab to Inhibit Osteoclast Formation and Activity

The Myeloma Cells Escape from Bone Marrow to Skin Extramedullary Localization upon Bortezomib Resistance: Role of CXCR4

Relationship Between Presence Of Osteolytic Lesions, Cytogenetic Features and Bone Marrow Levels Of Cytokines and Chemokines In Multiple Myeloma Patients: Role Of Chemokine (C-C motif) Ligand 20

Myeloma-Induced Osteocyte Death Was Blunted By Proteasome Inhibitors Through The Modulation Of Autophagy

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only